612 results on '"Haanen, John B. A. G."'
Search Results
2. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
3. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
4. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
5. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
6. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
7. Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma
8. Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
9. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
10. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
11. Developments in Solid Tumours
12. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
13. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
14. [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma
15. ASO Visual Abstract: Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
16. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
17. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
18. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
19. Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.
20. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
21. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
22. Immunotherapy for cancer treatment during pregnancy
23. A prediction model for response to immune checkpoint inhibition in advanced melanoma
24. Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma
25. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
26. Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune‐related adverse events of immune checkpoint inhibitors.
27. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
28. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
29. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
30. Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial.
31. IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
32. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
33. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus
34. Adoptive cellular therapies: the current landscape
35. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
36. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
37. COVID-19 vaccination: the VOICE for patients with cancer
38. Cytokines (IL-2, IFN GM-CSF etc) Melanoma
39. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
40. Radiotherapy, atezolizumab, and bevacizumab in rectal cancers with the aim of organ preservation: The TARZAN study.
41. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
42. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
43. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
44. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
45. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
46. Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
47. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
48. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
49. HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia
50. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.